ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Step count and symptom severity during cancer treatment using the Symptom Care at Home digital platform.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
contextP atients undergoing systemic cancer therapy still experience significant symptom burden. Electronic patient-reported outcomes (ePRO) monitoring and follow-up of symptoms has improved suffering, but limited work has explored combined subjective and objective measures. This secondary analysis explored the relationship between oncology symptoms and step count using the Symptom Care at Home (SCH) digital monitoring platform.
methodsParticipants reported 11 disease and treatment symptoms: fatigue, trouble sleeping, nausea and vomiting, pain, numbness or tingling, depressed mood, feeling nervous or anxious, trouble breathing, diarrhea, sore mouth, and trouble thinking or concentrating via ePRO and independently reported step count via Garmin activity monitors. Analysis included descriptive statistics and linear mixed-effect models to examine the relationship between symptom burden and step count.
resultsOf participants who provided Garmin activity monitors (n = 339), 18-5 (54%) reported ePRO symptoms and step counts. A mean 76.56 days of step count and 56 days of ePRO were reported. The mean step count was 3164.34 (SD = 2370.28). Using a scale of 0-10, our results indicate that a 1-point increase in total symptom severity burden is associated with a decrease of approximately 46 daily steps (B = - 45.94, p < 0.001). Individual symptom analysis found that a one-point symptom increase corresponded with a 165-step count decrease with a one-point increase in fatigue (B = - 165.33, p < 0.001), a 107-step decrease with increased nausea and vomiting (B = - 107.49, p < 0.001), and a 28-step reduction in pain.
conclusionsThis study demonstrates a relationship between ePRO and step count in patients undergoing systemic cancer treatment across diagnoses. Notably, fatigue was the most prevalent symptom impacting activity, even more prevalent than nausea, vomiting, and pain. This secondary analysis reflects the potential for utilizing combined reporting measures such as ePRO and step count to increase symptom reporting and clinical response for patients undergoing systemic cancer treatment.
Indexed as
Identifiers
40758176What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.